YY1 overexpression is associated with poor prognosis and metastasis-free survival in patients suffering osteosarcoma

Filomena de Nigris, Licciana Zanella, Francesco Cacciatore, Anna De Chiara, Flavio Fazioli, Gennaro Chiappetta, Gaetano Apice, Teresa Infante, Mario Monaco, Raffaele Rossiello, Gaetano De Rosa, Marco Alberghini, Claudio Napoli

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background: The polycomb transcription factor Yin Yang 1 (YY1) overexpression can be causally implicated in experimental tumor growth and metastasization. To date, there is no clinical evidence of YY1 involvement in outcome of patients with osteosarcoma. Prognosis of osteosarcoma is still severe and only few patients survive beyond five years. We performed a prospective immunohistochemistry analysis to correlate YY1 immunostaining with metastatic development and survival in a selected homogeneous group of patients with osteosarcoma.Methods: We studied 41 patients suffering from osteosarcoma (stage II-IVa). Multivariate analysis was performed using Cox proportional hazard regression to evaluate the correlation between YY1 expression and both metastasis development and mortality.Results: YY1 protein is not usually present in normal bone; in contrast, a high number of patients (61%) showed a high score of YY1 positive cells (51-100%) and 39% had a low score (10-50% positive cells). No statistical difference was found in histology, anatomic sites, or response to chemotherapy between the two degrees of YY1 expression. Cox regression analysis demonstrated that the highest score of YY1 expression was predictive of both low metastasis-free survival (HR = 4.690, 95%CI = 1.079-20.396; p = 0.039) and poor overall survival (HR = 8.353, 95%CI = 1.863-37.451 p = 0.006) regardless of the effects of covariates such as age, gender, histology and chemonecrosis.Conclusion: Overexpression of YY1 in primary site of osteosarcoma is associated with the occurrence of metastasis and poor clinical outcome.

Original languageEnglish
Article number472
JournalBMC Cancer
Volume11
DOIs
Publication statusPublished - Nov 2 2011

Fingerprint

Yin-Yang
Osteosarcoma
Neoplasm Metastasis
Survival
YY1 Transcription Factor
Histology
Transcription Factors
Multivariate Analysis
Immunohistochemistry
Regression Analysis
Bone and Bones
Drug Therapy
Mortality

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Genetics

Cite this

YY1 overexpression is associated with poor prognosis and metastasis-free survival in patients suffering osteosarcoma. / Nigris, Filomena de; Zanella, Licciana; Cacciatore, Francesco; Chiara, Anna De; Fazioli, Flavio; Chiappetta, Gennaro; Apice, Gaetano; Infante, Teresa; Monaco, Mario; Rossiello, Raffaele; Rosa, Gaetano De; Alberghini, Marco; Napoli, Claudio.

In: BMC Cancer, Vol. 11, 472, 02.11.2011.

Research output: Contribution to journalArticle

@article{f19f2ee95ef64c2da3b7d84d2bd9d411,
title = "YY1 overexpression is associated with poor prognosis and metastasis-free survival in patients suffering osteosarcoma",
abstract = "Background: The polycomb transcription factor Yin Yang 1 (YY1) overexpression can be causally implicated in experimental tumor growth and metastasization. To date, there is no clinical evidence of YY1 involvement in outcome of patients with osteosarcoma. Prognosis of osteosarcoma is still severe and only few patients survive beyond five years. We performed a prospective immunohistochemistry analysis to correlate YY1 immunostaining with metastatic development and survival in a selected homogeneous group of patients with osteosarcoma.Methods: We studied 41 patients suffering from osteosarcoma (stage II-IVa). Multivariate analysis was performed using Cox proportional hazard regression to evaluate the correlation between YY1 expression and both metastasis development and mortality.Results: YY1 protein is not usually present in normal bone; in contrast, a high number of patients (61{\%}) showed a high score of YY1 positive cells (51-100{\%}) and 39{\%} had a low score (10-50{\%} positive cells). No statistical difference was found in histology, anatomic sites, or response to chemotherapy between the two degrees of YY1 expression. Cox regression analysis demonstrated that the highest score of YY1 expression was predictive of both low metastasis-free survival (HR = 4.690, 95{\%}CI = 1.079-20.396; p = 0.039) and poor overall survival (HR = 8.353, 95{\%}CI = 1.863-37.451 p = 0.006) regardless of the effects of covariates such as age, gender, histology and chemonecrosis.Conclusion: Overexpression of YY1 in primary site of osteosarcoma is associated with the occurrence of metastasis and poor clinical outcome.",
author = "Nigris, {Filomena de} and Licciana Zanella and Francesco Cacciatore and Chiara, {Anna De} and Flavio Fazioli and Gennaro Chiappetta and Gaetano Apice and Teresa Infante and Mario Monaco and Raffaele Rossiello and Rosa, {Gaetano De} and Marco Alberghini and Claudio Napoli",
year = "2011",
month = "11",
day = "2",
doi = "10.1186/1471-2407-11-472",
language = "English",
volume = "11",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central Ltd.",

}

TY - JOUR

T1 - YY1 overexpression is associated with poor prognosis and metastasis-free survival in patients suffering osteosarcoma

AU - Nigris, Filomena de

AU - Zanella, Licciana

AU - Cacciatore, Francesco

AU - Chiara, Anna De

AU - Fazioli, Flavio

AU - Chiappetta, Gennaro

AU - Apice, Gaetano

AU - Infante, Teresa

AU - Monaco, Mario

AU - Rossiello, Raffaele

AU - Rosa, Gaetano De

AU - Alberghini, Marco

AU - Napoli, Claudio

PY - 2011/11/2

Y1 - 2011/11/2

N2 - Background: The polycomb transcription factor Yin Yang 1 (YY1) overexpression can be causally implicated in experimental tumor growth and metastasization. To date, there is no clinical evidence of YY1 involvement in outcome of patients with osteosarcoma. Prognosis of osteosarcoma is still severe and only few patients survive beyond five years. We performed a prospective immunohistochemistry analysis to correlate YY1 immunostaining with metastatic development and survival in a selected homogeneous group of patients with osteosarcoma.Methods: We studied 41 patients suffering from osteosarcoma (stage II-IVa). Multivariate analysis was performed using Cox proportional hazard regression to evaluate the correlation between YY1 expression and both metastasis development and mortality.Results: YY1 protein is not usually present in normal bone; in contrast, a high number of patients (61%) showed a high score of YY1 positive cells (51-100%) and 39% had a low score (10-50% positive cells). No statistical difference was found in histology, anatomic sites, or response to chemotherapy between the two degrees of YY1 expression. Cox regression analysis demonstrated that the highest score of YY1 expression was predictive of both low metastasis-free survival (HR = 4.690, 95%CI = 1.079-20.396; p = 0.039) and poor overall survival (HR = 8.353, 95%CI = 1.863-37.451 p = 0.006) regardless of the effects of covariates such as age, gender, histology and chemonecrosis.Conclusion: Overexpression of YY1 in primary site of osteosarcoma is associated with the occurrence of metastasis and poor clinical outcome.

AB - Background: The polycomb transcription factor Yin Yang 1 (YY1) overexpression can be causally implicated in experimental tumor growth and metastasization. To date, there is no clinical evidence of YY1 involvement in outcome of patients with osteosarcoma. Prognosis of osteosarcoma is still severe and only few patients survive beyond five years. We performed a prospective immunohistochemistry analysis to correlate YY1 immunostaining with metastatic development and survival in a selected homogeneous group of patients with osteosarcoma.Methods: We studied 41 patients suffering from osteosarcoma (stage II-IVa). Multivariate analysis was performed using Cox proportional hazard regression to evaluate the correlation between YY1 expression and both metastasis development and mortality.Results: YY1 protein is not usually present in normal bone; in contrast, a high number of patients (61%) showed a high score of YY1 positive cells (51-100%) and 39% had a low score (10-50% positive cells). No statistical difference was found in histology, anatomic sites, or response to chemotherapy between the two degrees of YY1 expression. Cox regression analysis demonstrated that the highest score of YY1 expression was predictive of both low metastasis-free survival (HR = 4.690, 95%CI = 1.079-20.396; p = 0.039) and poor overall survival (HR = 8.353, 95%CI = 1.863-37.451 p = 0.006) regardless of the effects of covariates such as age, gender, histology and chemonecrosis.Conclusion: Overexpression of YY1 in primary site of osteosarcoma is associated with the occurrence of metastasis and poor clinical outcome.

UR - http://www.scopus.com/inward/record.url?scp=80055115344&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80055115344&partnerID=8YFLogxK

U2 - 10.1186/1471-2407-11-472

DO - 10.1186/1471-2407-11-472

M3 - Article

C2 - 22047406

AN - SCOPUS:80055115344

VL - 11

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

M1 - 472

ER -